Alumis Inc. key statistics and ratios
In fiscal 2025, Alumis Inc. had return on equity of -80.8%, an operating margin of -1886.9%, debt equal to 0.0% of equity and a current ratio of 4.34. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|
| Operating margin | <−999% | <−999% |
| Net margin | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% |
| Return on equity | −80.8% | −116.5% |
| Return on assets | −59.1% | −90.3% |
| Asset turnover | 0.06 | 0.02 |
| Current ratio | 4.34 | 6.74 |
| Debt to equity | 0.0% | 0.0% |
| R&D as % of revenue | >999% | >999% |
| Capital spending as % of revenue | 2.7% | 5.4% |
| Quarter | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|
| Operating margin | −583.9% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | −569.1% | >999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | −462.3% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Current ratio | 3.73 | 6.05 | 6.01 | 4.34 | 7.51 | 6.74 |
| R&D as % of revenue | 555.7% | >999% | >999% | >999% | >999% | >999% |
Financial health
- Short-term assets cover short-term liabilities $514m of assets due within a year against $76m of liabilities due within a year.
- Short-term assets cover long-term liabilities $514m short-term assets against $32m of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Compare with peers
- Evaxion A/s statistics
- Roivant Sciences Ltd. statistics
- Adagene Inc. statistics
- Tscan Therapeutics, Inc. statistics
- Coya Therapeutics, Inc. statistics
Head to head: ALMS vs EVAXALMS vs ROIVADAG vs ALMS
More: Biotechnology stocks compared, Health Care sector, rankings of US companies